Humanigen Sets Date for Virtual Annual Shareholders Meeting
March 19 2021 - 6:00AM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm’ with its lead drug
candidate, lenzilumab™, announced today that its board of directors
has scheduled the corporation's 2021 Annual Meeting of Shareholders
(the “Meeting”) for June 17, 2021 in a virtual-only format via the
internet. The record date for shareholders to vote at the meeting
is April 21, 2021.
Additional information confirming how shareholders may vote
before or during the Meeting, as well as the time of the virtual
Meeting and how to access it as a shareholder, will be included in
the company’s proxy statement to be separately provided to
shareholders. In order to streamline the virtual meeting process,
the company strongly encourages shareholders to vote in advance of
the Meeting.
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of cancers and infectious
diseases via its novel, cutting-edge GM-CSF neutralization, and
gene-knockout platforms. Humanigen believes that its GM-CSF
neutralization and gene-editing platform technologies have the
potential to reduce the inflammatory cascade associated with
coronavirus infection. Humanigen’s immediate focus is to prevent or
minimize the cytokine release syndrome that precedes severe lung
dysfunction and ARDS in serious cases of SARS-CoV-2 infection.
Humanigen is also focused on creating next-generation combinatory
gene-edited CAR-T therapies using strategies to improve efficacy
while employing GM-CSF gene knockout technologies to control
toxicity. In addition, Humanigen is developing its own portfolio of
proprietary first-in-class EphA3-CAR-T for various solid cancers
and EMR1-CAR-T for various eosinophilic disorders. Humanigen is
also exploring the effectiveness of its GM-CSF neutralization
technologies (either through the use of lenzilumab as a
neutralizing antibody or through GM-CSF gene knockout) in
combination with other CAR-T, bispecific or natural killer (NK) T
cell engaging immunotherapy treatments to break the
efficacy/toxicity linkage, including to prevent and/or treat
graft-versus-host disease (GvHD) in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). Additionally,
Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in
combination with Yescarta® (axicabtagene ciloleucel) in patients
with relapsed or refractory large B-cell lymphoma in a clinical
collaboration. For more information, visit www.humanigen.com and
follow Humanigen on LinkedIn, Twitter and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210319005040/en/
Humanigen Media Grace Catlett RXMD Gcatlett@rxmedyn.com
516-318-8563
Humanigen Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From May 2023 to May 2024